Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S005 - EADV/AAD Joint Symposium

Thursday, July 26; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Discuss recent advances in vascular birthmarks and therapies for alopecia areata
  • Recognize the clinical spectrum of systemic sclerosis and scleroderma - like diseases
  • Improve approach to diagnosis and management of oncology patients treated with targeted therapies

Description

The EADV and AAD have joined forces in an effort to complement one another and provide the audience with an expanded perspective of topics of interest to dermatologists from true experts from both sides of the Atlantic Ocean. Speakers will discuss a diverse group of topics and their impact in caring for our patients. We will hear about new cancer treatments – specifically immunotherapies – and the ways that they affect the skin. New insights about vascular birthmarks will be discussed. Speakers will also be discussing scleroderma and scleroderma-like disorders, advances in alopecia areata treatment, vascular birthmark updates and atopic dermatitis.

Disclosures

  • Bolognia, Jean L., MD: Elsevier Inc. – O(IP);
  • Lebwohl, Mark, MD: AbbVie – I(Grants/Research Funding); Allergan, Inc. – C(H); Almirall – C(H); Amgen – I(Grants/Research Funding); Arcutis, Inc. – C(H); AstraZeneca – I(Grants/Research Funding); Avotres, Inc. – C(H); BirchBioMed – C(H); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(H); Cara Therapeutics – C(H); Castle Biosciences, Inc – C(H); Celgene Corporation – I(Grants/Research Funding); Clinuvel – I(Grants/Research Funding); Corrona, Inc. – O(H); Dermavant Sciences – C(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Incyte Corporation – I(Grants/Research Funding); Inozyme Pharma – C(H); Janssen Research & Development, LLC – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); Leo Pharma Inc – C(H); LEO Pharma, US – I(Grants/Research Funding); Medimmune – I(Grants/Research Funding); Meiji Seika Pharma Co., Ltd – C(H); Menlo Therapeutics – C(H); Mitsibushi Pharma – C(H); Neuroderm LTD – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Ortho Dermatologics – I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); SCIderm – I(Grants/Research Funding); Theravance Biopharma – C(H); UCB – I(Grants/Research Funding); Verrica Pharmaceuticals Inc – C(H); Vidac Pharma – I(Grants/Research Funding);
  • Lipsker, Dan, MD: no financial relationships exist with commercial interests.
  • Paller, Amy S., MD: AbbVie – I(NC); Amgen – C(H), I(NC); Amicus Therapeutics – C(H); Boehringer Ingelheim – C(H); BridgeBio Pharma, LLC – A(H), C(H); Castle Creek Pharmaceuticals – C(H); Celgene Corporation – I(NC); Chameleon Communications – C(H); Dermavant Sciences – C(H); Dermira – C(H); Eli Lilly and Company – C(H); Expanscience – Speaker/Faculty Education(H); Forte Biosciences – C(H); Galderma Laboratories, L.P. – C(H); Janssen Pharmaceuticals, Inc – I(NC); Leo Pharma Inc – I(Grants/Research Funding); Menlo Therapeutics – A(H), C(H); MorphoSys AG – C(H); Novartis Pharmaceuticals Corp. – C(H); Pfizer Inc. – C(H); Regeneron – C(H); Sanofi/Regeneron – A(H); Stiefel a GSK company – C(H); TARGET Pharma – C(H); Theravance Biopharma – C(H); Union Therapeutics – C(H); Valeant Pharmaceuticals North America LLC – C(H); Verrica Pharmaceuticals Inc – C(H);
  • Pellacani, Giovanni, MD: Mavig – SP(H);
  • Rocken, Martin, MD: AB Science Pharmaceutical Company – I(Grants/Research Funding); Abbott Laboratories – I(Grants/Research Funding); Abbott Pharmaceuticals – I(Grants/Research Funding); AbbVie – I(Grants/Research Funding); Almirall – I(Grants/Research Funding); AstraZeneca – I(Grants/Research Funding); Bayer – I(Grants/Research Funding); Biogen – I(Grants/Research Funding); Bristol-Myers Squibb – I(Grants/Research Funding), SH(ST); Celgene – I(Grants/Research Funding); Galderma Laboratories, L.P. – I(Grants/Research Funding); Janssen-Cilag – I(Grants/Research Funding); Johnson and Johnson – I(Grants/Research Funding); Leo Pharma Inc. – I(Grants/Research Funding); Lilly ICOS LLC – I(Grants/Research Funding); Merck & Co., Inc – I(Grants/Research Funding), SH(ST); MSD – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Roche Laboratories – I(Grants/Research Funding); sanofi-aventis – I(Grants/Research Funding);
  • Schwarz, Thomas, MD: med update GmbH – SP(H); Pfizer Inc. – SP(H);
  • Tomecki, Kenneth J., MD: no financial relationships exist with commercial interests.
Schedule
Thursday, July 26
1:00 PM
Dr. Paller / Pediatric Atopic Dermatitis – New Developments, New Perspectives
1:30 PM
Dr. Lipsker / Lupus: Pathogenesis and Therapy
2:00 PM
Dr. Lebwohl / Psoriasis and Biologic Rx: the Beat Goes On
2:30 PM
Dr. Schwarz / Photomedicine 2018: Role and Relevance
3:00 PM
Dr. Bolognia / Melanoma Rx: Cutaneous Complications
3:30 PM
Dr. Pellacani / Dermoscopy and Pigmented Lesions
Event Details
  • Date
    Thursday, July 26
  • Time
    1:00 PM - 4:00 PM
  • Location
    Regency Ballroom A
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
  • Kenneth J. Tomecki, MD, FAAD
  • Martin Rocken, MD
Speakers